Reviewing Seelos Therapeutics Inc. (SEEL)’s and CRISPR Therapeutics AG (NASDAQ:CRSP)’s results – MS Wkly

Posted: October 18, 2019 at 1:44 pm

We are contrasting Seelos Therapeutics Inc. (NASDAQ:SEEL) and CRISPR Therapeutics AG (NASDAQ:CRSP) on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Table 1 demonstrates Seelos Therapeutics Inc. and CRISPR Therapeutics AGs top-line revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.


The Current Ratio of Seelos Therapeutics Inc. is 2.5 while its Quick Ratio stands at 2.5. The Current Ratio of rival CRISPR Therapeutics AG is 15.8 and its Quick Ratio is has 15.8. CRISPR Therapeutics AG is better equipped to clear short and long-term obligations than Seelos Therapeutics Inc.

Analyst Ratings

Seelos Therapeutics Inc. and CRISPR Therapeutics AG Ratings and Recommendations are available on the next table.

Meanwhile, CRISPR Therapeutics AGs consensus target price is $62, while its potential upside is 63.55%.

Institutional & Insider Ownership

Institutional investors held 10.4% of Seelos Therapeutics Inc. shares and 50% of CRISPR Therapeutics AG shares. 18.48% are Seelos Therapeutics Inc.s share held by insiders. Insiders Comparatively, held 2% of CRISPR Therapeutics AG shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Seelos Therapeutics Inc. had bearish trend while CRISPR Therapeutics AG had bullish trend.


CRISPR Therapeutics AG beats on 7 of the 10 factors Seelos Therapeutics Inc.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Go here to read the rest:
Reviewing Seelos Therapeutics Inc. (SEEL)'s and CRISPR Therapeutics AG (NASDAQ:CRSP)'s results - MS Wkly

Related Post

Comments are closed.